m_and_a
confidence high
sentiment positive
materiality 0.90
Onconetix agrees to reverse merger with Ocuvex; Ocuvex holders to own 90% of combined company
Onconetix, Inc.
- Onconetix acquires Ocuvex; Ocuvex holders get 90% of combined co, Onconetix holders 10%.
- Post-close board: 7 directors (5 Ocuvex, 2 Onconetix); closing targeted Q4 2025.
- Series C Preferred conversion price reduced to $3.50 effective through July 31, 2025.
- Andrew Oakley elected Lead Independent Director, to receive $36,000/month.
- Nasdaq compliance regained; subject to Mandatory Panel Monitor through July 2026.
item 1.01item 5.02item 8.01item 9.01
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.